These findings indicated that raltegravir enhanced endothelial barrier integrity, thereby reducing ALI-associated inflammation via modulating HMGB1/TLR4/NF-κB signaling and inhibiting NLRP3 activation. The gene discussed is HMGB1; the disease is acute respiratory distress syndrome.